Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin

References

• AilaniRKAlimchandaniAHidalgoJCephalosporin-resistant pneumococcal pneumonia:does it, affect outcome?Respir Med2002968051112412980
   PubMed Web of Science ®Google Scholar
• AllenABygateEClarkDThe effect of food on the bioavailability of oral gemifloxacin in healthy volunteersInt J Antimicrob Agents2000a16455011185412
   PubMed Web of Science ®Google Scholar
• AllenABygateEFaesselHThe effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteersInt J Antimicrob Agents2000b15283910929878
   PubMed Web of Science ®Google Scholar
• AllenABygateEVousdenMMultiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteersAntimicrob Agents Chemother200145540511158752
   PubMed Web of Science ®Google Scholar
• AllenAVousdenMPorterAEffect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteersChemotherapy1999455041110567782
   PubMed Web of Science ®Google Scholar
• AppelbaumPCGillespieSHBurleyCJAntimicrobial selection for community-acquired lower respiratory tract infections in the 21st century:a review of gemifloxacinInt J Antimicrob Agents2004235334615194123
   PubMed Web of Science ®Google Scholar
• ArancibiaFBauerTTEwigSCommunity-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosisArch Intern Med200216218495812196083
   PubMed Web of Science ®Google Scholar
• BallPQuinolone generations:natural history or natural selection?J Antimicrob Chemother200046Suppl T1172410997595
   PubMed Web of Science ®Google Scholar
• BallPFileTMTwynholmMEfficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infectionsInt J Antimicrob Agents200118192711463522
   PubMed Web of Science ®Google Scholar
• BartlettJGDowellSFMandellLAPractice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of AmericaClin Infect Dis2000313478210987697
   PubMed Web of Science ®Google Scholar
• BhavnaniSMAndesDRGemifloxacin for the treatment of respiratory tract infections:in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safetyPharmacotherapy2005257174015899734
   PubMed Web of Science ®Google Scholar
• BroskeyJColemanKGwynnMNEfflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniaeJ Antimicrob Chemother200045Suppl 195910824039
   PubMed Web of Science ®Google Scholar
• BrueggemannABCoffmanSLRhombergPFluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994–1995Antimicrob Agents Chemother200246680811850248
   PubMed Web of Science ®Google Scholar
• ChoiEHLeeHJClinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean childrenClin Infect Dis1998261346549636861
   PubMed Web of Science ®Google Scholar
• CizmanMPokornMSemeKInfluence of increased macrolide consumption on macrolide resistance of common respiratory pathogensEur J Clin Microbiol Infect Dis199918522410482034
   PubMed Web of Science ®Google Scholar
• Clavo-SanchezAJGiron-GonzalezJALopez-PrietoDMultivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae:a multicenter studyClin Infect Dis199724105299195057
   PubMed Web of Science ®Google Scholar
• Corporation OPFactive (gemifloxacin) package insertMed Lett Drugs Ther200478915452464
   PubMed Web of Science ®Google Scholar
• DaviesTAKellyLMHoellmanDBActivities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalisAntimicrob Agents Chemother2000a44633910681330
   PubMed Web of Science ®Google Scholar
• DaviesTAKellyLMPankuchGAAntipneumococcal activities of gemifloxacin compared to those of nine other agentsAntimicrob Agents Chemother2000b443041010639354
   PubMed Web of Science ®Google Scholar
• DeeksSLPalacioRRuvinskyRRisk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working GroupPediatrics1999103409139925833
   PubMed Web of Science ®Google Scholar
• DeshpandeLMJonesRNAntimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)Diagn Microbiol Infect Dis2000371394210863108
   PubMed Web of Science ®Google Scholar
• FileTMCommunity-acquired pneumoniaLancet20033621991200114683661
   PubMed Web of Science ®Google Scholar
• FileTMJrNiedermanMSAntimicrobial therapy of community-acquired pneumoniaInfect Dis Clin North Am2004189931016xi15555836
   PubMed Web of Science ®Google Scholar
• FileTMJrSchlemmerBGarauJEfficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia:a randomized, double-blind comparison with trovafloxacinJ Antimicrob Chemother200148677411474633
   PubMed Web of Science ®Google Scholar
• FileTMJrTillotsonGSGemifloxacin:a new, potent fluoroquinolone for the therapy of lower respiratory tract infectionsExpert Rev Anti Infect Ther200428314315566328
   PubMedGoogle Scholar
• FineMJAubleTEYealyDMA prediction rule to identify low-risk patients with community-acquired pneumoniaN Engl J Med1997336243508995086
   PubMed Web of Science ®Google Scholar
• FirsovAAZinnerSHLubenkoIGemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model:prediction of the equivalent AUC/MIC breakpoints and dosesInt J Antimicrob Agents2000164071411118849
   PubMed Web of Science ®Google Scholar
• FogartyCGoldschmidtRBushKBacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacinClin Infect Dis200031613510987733
   PubMed Web of Science ®Google Scholar
• ForwardKRThe epidemiology of penicillin resistance in Streptococcus pneumoniaeSemin Respir Infect1999142435410501312
   PubMedGoogle Scholar
• FriedlandIRComparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal diseasePediatr Infect Dis J199514885908584317
   PubMed Web of Science ®Google Scholar
• GarauJRole of beta-lactam agents in the treatment of community-acquired pneumoniaEur J Clin Microbiol Infect Dis200524839915696306
   PubMed Web of Science ®Google Scholar
• Garcia-RodriguezJAMunoz BellidoJLThe role of fluoroquinolones in respiratory tract infections:community acquired pneumoniaInt J Antimicrob Agents200016281511091048
   PubMed Web of Science ®Google Scholar
• GillespieSHVoelkerLLAmblerJEFluoroquinolone resistance in Streptococcus pneumoniae:evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutationMicrob Drug Resist20039172412705679
   PubMed Web of Science ®Google Scholar
• GillespieSHVoelkerLLDickensAEvolutionary barriers to quinolone resistance in Streptococcus pneumoniaeMicrob Drug Resist20028798412118521
   PubMed Web of Science ®Google Scholar
• GotfriedMHComparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistanceClin Ther20002221410688386
   PubMed Web of Science ®Google Scholar
• HeatonVJAmblerJEFisherLMPotent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitroAntimicrob Agents Chemother2000443112711036032
   PubMed Web of Science ®Google Scholar
• HeatonVJGoldsmithCEAmblerJEActivity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanismsAntimicrob Agents Chemother1999432998300010582896
   PubMed Web of Science ®Google Scholar
• HongCYDiscovery of gemifloxacin (Factive, LB20304a): a quinolone of a new generationFarmaco20015641411347965
   PubMedGoogle Scholar
• JohnsonAPSheppardCLHarnettSJEmergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in EnglandJ Antimicrob Chemother2003529536014585858
   PubMed Web of Science ®Google Scholar
• JokinenCHeiskanenLJuvonenHMicrobial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern FinlandClin Infect Dis20013211415411283803
   PubMed Web of Science ®Google Scholar
• KelleyMAWeberDJGilliganPBreakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycinClin Infect Dis20003110081111049784
   PubMed Web of Science ®Google Scholar
• LeophontePFileTFeldmanCGemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal originRespir Med2004987082015303634
   PubMed Web of Science ®Google Scholar
• LewisRJTsaiFTWigleyDBMolecular mechanisms of drug inhibition of DNA gyraseBioessays199618661718760340
   PubMed Web of Science ®Google Scholar
• LimWSMacfarlaneJTBoswellTCStudy of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital:implications for management guidelinesThorax20015629630111254821
   PubMed Web of Science ®Google Scholar
• LimWSvan der EerdenMMLaingRDefining community acquired pneumonia severity on presentation to hospital:an international derivation and validation studyThorax2003583778212728155
   PubMed Web of Science ®Google Scholar
• LodeHFileTMJrMandellLOral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia:a randomized, open-label, multicenter study of clinical efficacy and tolerabilityClin Ther20022419153612501883
   PubMed Web of Science ®Google Scholar
• LonksJRGarauJGomezLFailure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniaeClin Infect Dis2002355566412173129
   PubMed Web of Science ®Google Scholar
• MarcheseADebbiaEASchitoGCComparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander ProjectJ Antimicrob Chemother200046Suppl T111510997594
   PubMed Web of Science ®Google Scholar
• McCloskeyLMooreTNiconovichNIn vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USAJ Antimicrob Chemother200045Suppl 1132110824027
   PubMed Web of Science ®Google Scholar
• MorrisseyIGeorgeJTPurification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolonesJ Antimicrob Chemother200045Suppl 1101610824040
   PubMed Web of Science ®Google Scholar
• MusherDMDowellMEShortridgeVDEmergence of macrolide resistance during treatment of pneumococcal pneumoniaN Engl J Med2002346630111856810
   PubMed Web of Science ®Google Scholar
• NiedermanMSMandellLAAnzuetoAGuidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and preventionAm J Respir Crit Care Med200116317305411401897
   PubMed Web of Science ®Google Scholar
• O’DonnellJAGeloneSPFluoroquinolonesInfect Dis Clin North Am200014489513xi10829268
   PubMed Web of Science ®Google Scholar
• OncuSErdemHPahsaATherapeutic options for pneumococcal pneumonia in TurkeyClin Ther2005276748316117975
   PubMed Web of Science ®Google Scholar
• OncuSPunarMEraksoyHComparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolatesChemotherapy2004509810015211085
   PubMed Web of Science ®Google Scholar
• OsterPZanchiACrestiSPatterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility ratesAntimicrob Agents Chemother1999432510210508033
   PubMed Web of Science ®Google Scholar
• PaganinFLilienthalFBourdinASevere community-acquired pneumonia:assessment of microbial aetiology as mortality factorEur Respir J2004247798515516672
   PubMed Web of Science ®Google Scholar
• PallaresRFenollALinaresJThe epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolonesInt J Antimicrob Agents200322Suppl 1S1524 discussion S25–614512221
   PubMed Web of Science ®Google Scholar
• PallaresRLinaresJVadilloMResistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, SpainN Engl J Med1995333474807623879
   PubMed Web of Science ®Google Scholar
• ShortridgeVDDoernGVBrueggemannABPrevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994–1995Clin Infect Dis1999291186810524961
   PubMed Web of Science ®Google Scholar
• Van KerkhovenDPeetermansWEVerbistLBreakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactamsJ Antimicrob Chemother200351691612615872
   PubMed Web of Science ®Google Scholar
• YagueGMorrisJEPanXSCleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolonesAntimicrob Agents Chemother200246413911796351
   PubMed Web of Science ®Google Scholar
• YooBKTrillerDMYongCSGemifloxacin:a new fluoroquinolone approved for treatment of respiratory infectionsAnn Pharmacother20043812263515187209
   PubMed Web of Science ®Google Scholar
• YuVLChiouCCFeldmanCAn international prospective study of pneumococcal bacteremia:correlation with in vitro resistance, antibiotics administered, and clinical outcomeClin Infect Dis200337230712856216
   PubMed Web of Science ®Google Scholar
• ZhanelGGNoreddinAMPharmacokinetics and pharmacodynamics of the new fluoroquinolones:focus on respiratory infectionsCurr Opin Pharmacol200114596311764770
   PubMedGoogle Scholar